To the Editor In their multicenter cohort study published recently in JAMA Oncology, Samadder et al1 analyzed a gene panel of 2984 unselected patients with solid tumors. They identified pathogenic germline variants (PGVs) in 397 patients and concluded that this approach identified more PGV carriers than current guidelines for germline cancer genetic testing.